国际肝病采访王宇明教授

Q2：It is reported that low dose pegylated interferon-alpha treatment for patients with hepatitis C who do not respond to the standard antiviral treatment may prevent the complication of cirrhosis. Can you comment on the current situation about that?
Q2：有研究认为对于标准抗病毒治疗（干扰素联合利巴韦林）未产生病毒学应答的丙肝肝硬化患者，采用小剂量聚乙二醇干扰素(PEG-IFN)α-2b抗丙肝病毒治疗，可以预防肝硬化并发症，您能介绍一下这方面的研究情况吗？

Q3：Some compensated patients with hepatitis C companied with hypersplenism can not be tolerant with the interferon treatment for pancytopenia especially thrombocytopenia， do you think splenectomy or partial splenic artery embolization as a feasible choice for these patients to proceed the antiviral therapy?
有些代偿期丙肝肝硬化患者由于脾功能亢进在干扰素治疗过程中出现全血细胞减少尤其是血小板减少而不能耐受，您认为行脾切除或部分脾动脉栓塞术是继续抗病毒治疗的可行办法吗？